Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2005 by Dr. Louis A. Cannon, BioStar Capital is a venture capital firm based in the United States. The firm manages five venture capital funds and employs a team of healthcare clinicians, executives, and financial professionals. BioStar Capital focuses on early- and late-stage investments primarily in cardiology, orthopedics, and robotics.
BioStar Capital invests in smart devices, robotics, and minimally invasive solutions that address unmet patient needs in healthcare. Their investment strategy includes opportunities in cost-reduction technology and outpatient-center technology, with a disciplined evaluation process assessing commercial relevance and clinical impact. The firm targets seed, Series A, Series B, and growth equity stages.
BioStar Capital has notable active exits including Transcatheter renal denervation for hypertension, Pulsatile Intravascular Lithotripsy (PIVL) for calcified arteries, and robotic microsurgery using NanoWrist instruments. Other exits include technologies for treating pulmonary hypertension and long-term continuous glucose monitoring for diabetes management.
Email your deck to info@biostarcapital.com for consideration.
Yes, BioStar Capital often leads investment rounds, particularly in early-stage opportunities within their focus sectors.
The firm is open to follow-on investments, especially if the portfolio company demonstrates significant growth potential and aligns with their investment thesis.
BioStar Capital manages five venture capital funds, although specific fund sizes are not publicly disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.